Cyberonics, Inc. (CYBX) - NASDAQ
  • Aug. 20, 2015, 9:14 AM
    | Aug. 20, 2015, 9:14 AM
  • Feb. 26, 2015, 12:57 PM
    | Feb. 26, 2015, 12:57 PM | 7 Comments
  • Jan. 5, 2015, 5:35 PM
    • Top gainers, as of 5:15 p.m.: NERV +87.5%. ANTH +11.0%. WTI +10.2%. GST +9.0%. RICE +8.8%.
    • Top losers, as of 5:15 p.m.: CYBX -8.1%. CERS -4.9%. ECR -3.1%. JNUG -2.7%. AU -2.5%.
    | Jan. 5, 2015, 5:35 PM
  • Nov. 20, 2014, 12:46 PM
    | Nov. 20, 2014, 12:46 PM
  • Aug. 22, 2013, 12:12 PM
    • Cyberonics (CYBX -2.9%) slips despite an FQ1 earnings beat.
    • EPS were Up 26% from the same quarter last year.
    • Sales were Up 12% year over year, led by strength in Europe.
    • Worldwide unit sales +9.8%.
    • Record U.S. net product sales of $56.4M, +10.8%.
    • For FY14, the company reaffirms its outlook of sales in the range of $279M - $283M and EPS of $1.93 - $2.01, splitting the Street view of $281M in sales on earnings of $1.98 per share.
    | Aug. 22, 2013, 12:12 PM
  • Jun. 5, 2013, 12:28 PM
    Cyberonics (CYBX +4.3%) moves up after FQ4 earnings beat expectations, fueled by record sales and strong international growth. International unit sales surged a record 27% in the quarter, outpacing the 17% growth seen in US, which was also a record. For FY14, the company ups expectations, now expecting sales in the range of $279M to $283M, above Street estimates of $276M.
    | Jun. 5, 2013, 12:28 PM
  • May 29, 2013, 11:42 AM

    Canaccord reiterates its Buy recommendation on Cyberonics (CYBX -1.9%), saying the fundamental business "remains intact" after the company's reconsideration request for VNS Therapy was denied by the Centers for Medicare and Medicaid (price target lowered to $49 from $59).

    | May 29, 2013, 11:42 AM
  • May 29, 2013, 11:14 AM

    Cyberonics (CYBX -2.4%) falls after saying the Centers for Medicare and Medicaid Services will not reconsider a decision to deny coverage for the company's VNS Therapy in patients with treatment-resistant depression. CEO Dan Moore is "very disappointed in the decision." (PR)

    | May 29, 2013, 11:14 AM | 1 Comment
  • Feb. 22, 2013, 9:10 AM
    Premarket gainers: WBMD +19%. ARUN +14%. FIRE +13%. JOEZ +11%. CYBX +8%. MRVL +5%. GLUU +5%. HPQ +5%.
    Losers: ETRM -17%. RAX -6%. FRO -6%.
    | Feb. 22, 2013, 9:10 AM
  • Jan. 23, 2013, 5:41 PM
    After-hours top gainers, as of 5:15 p.m.: SWFT +10%. CYBX +9%. NAK +8%. FFIV +5%. YAVY +4%.
    After-hours top losers: CRUS -7%. AAPL -6%. SWKS -6%. HERO -5%. ALTR -5%.
    | Jan. 23, 2013, 5:41 PM | 3 Comments
  • Jan. 23, 2013, 3:42 PM

    More on Cyberonics (CYBX -7.6%): The company responds to TheStreetSweeper report, saying that it generally describes information that has been in the public domain for years and it doesn't "accurately characterize the benefit that VNS therapy provides patients and the opportunities for the company." The company added it's unaware of any whistleblower lawsuit related to the employment dispute. Dougherty & Co. called the blog post wildly inaccurate and misleading, while separately, Sidoti upgrades the stock to Buy on the weakness..

    | Jan. 23, 2013, 3:42 PM
  • Jan. 23, 2013, 3:31 PM

    Shares of Cyberonics (CYBX -7.6%) take a hit today after a report from the short-seller blog TheStreetSweeper raised questions about the science behind CYBX's VNS therapy, an implantable device that is similar to a pacemaker and stimulates major nerves. It also raised questions about a "whistleblower event" in an employment lawsuit against the company, alleging the company pressured its sales staff to have surgeons prematurely schedule battery replacements for the devices, which required surgery.

    | Jan. 23, 2013, 3:31 PM
  • Nov. 16, 2012, 12:42 PM

    Cyberonics (CYBX +11%) gets a big boost today from a solid FQ2 earnings beat. Net fiscal earnings rose 50%, thanks in part to a warrant-liability gain. The company also raised its full-year earnings estimate, now expecting to earn between $1.56 and $1.62 per share, above its June forecast of $1.49 to $1.59, and increased its sales guidance by $5 million, now expecting around $246M to $249M in sales.

    | Nov. 16, 2012, 12:42 PM
  • Aug. 29, 2012, 3:58 PM

    Cyberonics (CYBX +7.2%) shares hit an all-time high after reporting the better-than-expected FQ1 results, which prompts an upgrade from Canaccord to Buy from Hold. The firm says "our previous concerns about the impact of a competitive drug entering the market and a slowdown in replacement sales have not played out to our pessimistic expectations."

    | Aug. 29, 2012, 3:58 PM
  • Aug. 28, 2012, 9:10 AM
    Premarket gainers: SBX +33%. MOV +15%. CYBX +9%. PVH +5%. MCP +5%.
    Losers: CPRX -22%.
    | Aug. 28, 2012, 9:10 AM
  • Jun. 28, 2012, 11:32 AM

    The Supreme Court opinion on the Healthcare Act means that medical device makers still face a 2.3% tax on domestic sales starting next year unless they can persuade Congress to repeal it. Shares are sliding: MDT -1.2%, BSX -2.7%, STJ -1%, EW 1.1%, SYK -1.9%, ATRC -4.7%, CYBX -1.6%.

    | Jun. 28, 2012, 11:32 AM
Company Description
Cyberonics Inc is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure.
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States